Tumor, node and metastasis classification of lung cancer - M1a versus M1b - Analysis of M descriptors and other prognostic factors

Lung Cancer

Volumn 84, Issue 2, 2014, Pages 182-189

  Sánchez de Cos Escuín, Julio ^a,b   Abal Arca, José ^c   Melchor Íñiguez, Rosario ^d   Miravet Sorribes, Luis ^e   Núñez Ares, Ana ^c   Hernández Hernández, Jesús R ^f   García Arangüena, Luis ^g   Núñez Delgado, Manuel ^h   Pavón Fernández, Ma José ⁱ   Francisco Corral, Gloria ^j   de Esteban Júlvez, Leonardo ^k   González Budiño, Ma Teresa ^l   Abad Cavaco, Francisco ^m   Ansótegui Barrera, Emilio ^m   Andreo García, Felipe ⁿ   Serra Mitjans, Mireia ^o   Hernández Rodríguez, Helena ^p  

^a HOSPITAL SAN PEDRO DE ALCÁNTARA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c Pulmonology Section Complejo Hospitalario de Albacete   (Spain)

^d Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^e HOSPITAL DE LA PLANA   (Spain)

^f HOSPITAL NUESTRA SEÑORA DE SONSOLES   (Spain)

^g HOSPITAL SIERRALLANA   (Spain)

^h HOSPITAL DO MEIXOEIRO   (Spain)

ⁱ Hospital de Leganes   (Spain)

^j HOSPITAL GENERAL LA MANCHA CENTRO   (Spain)

^k HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

^l HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^m HOSPITAL UNIVERSITARIO LA FE   (Spain)

ⁿ HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^o HOSPITAL MÚTUA DE TERRASSA   (Spain)

^p Hospital Universitario de Tenerife   (Spain)

more..

Author keywords

Lung cancer; M1a; M1b; Metastasis; Non small cell lung cancer; Prognostic factors; TNM classification

Indexed keywords

ANTINEOPLASTIC AGENT;

ADRENAL METASTASIS; AGED; ARTICLE; BONE MARROW METASTASIS; BONE METASTASIS; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; FEMALE; FOLLOW UP; HUMAN; LIVER METASTASIS; LUNG NODULE; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; OVERALL SURVIVAL; PERITONEUM METASTASIS; PRIORITY JOURNAL; SKIN METASTASIS; TUMOR GROWTH; ADENOCARCINOMA; BRAIN TUMOR; CLASSIFICATION; CLINICAL TRIAL; KAPLAN MEIER METHOD; LUNG TUMOR; MORTALITY; MULTICENTER STUDY; NON SMALL CELL LUNG CANCER; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; SECONDARY; SQUAMOUS CELL CARCINOMA;

ADENOCARCINOMA; AGED; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; NEOPLASM STAGING; NEOPLASMS, SQUAMOUS CELL; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES;

EID: 84899475653     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2014.02.006     Document Type: Article

References (26)

1. Rami-Porta R., Ball D., Crowley J., Giroux D.J., Jett J., Travis W.D., et al. The IASLC lung cancer staging project: proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2007, 2:603-612.
2. Goldstraw P., Crowley J., Chansky K., Giroux D.J., Groome P.A., Rami-Porta R., et al. The IASLC lung cancer staging project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol 2007, 2:706-714.
3. Postmus P.E., Brambilla E., Chansky K., Crowley J., Goldstraw P., Patz E.F., et al. The IASLC lung cancer staging project: proposals for the revision of the M descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol 2007, 2:686-693.
4. Groome P.A., Bolejack V., Crowley J.J., Kennedy C., Krasnik M., Sobin L.H., et al. The IASLC lung cancer staging project. Validation of the proposals for the revision of the T, N, and M descriptors and consequent staging groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumors. J Thorac Oncol 2007, 2:694-705.
5. Goldstraw P., editor. The 7th edition of TNM in lung cancer: What now? J Thorac Oncol 2009;7:671-3.
6. Giroux D.J., Rami-Porta R., Chansky K., Crowley J.J., Groome P.A., Postmus P.E., et al. The IASLC lung cancer staging project, data elements for the prospective project. J Thorac Oncol 2009, 4:679-683.
7. Sánchez de Cos Escuín J., Serra Mitjans M., Hernández Hernández J., Hernández Rodríguez H. Registro del grupo cooperativo de cáncer de pulmón- II de la Sociedad Española de Neumología y Cirugía Torácica, Estudio descriptivo. Arch Bronconeumol 2013, 49:462-467. otros miembros del GCCB-II.
8. IASLC Lung Cancer Staging Project. ; 2013. https://prodc.crab.org/iaslc.
9. Sculier J.-P., Chansky K., Crowley J.J., Van Meerbeck J., Goldstrw P. The impact of additional prognostic factors on survival and their relationship with the anatomical extent of disease expressed by the 6th edition of the TNM classification of malignant tumors and the proposals for the 7th edition. J Thorac Oncol 2008, 3:457-466.
10. Kawaguchi T., Takada M., Kubo A., Matsamura A., Fukai S., Tamura A. Performance status and smoking status are independent favorable prognostic factors for survival in non-small cell lung cancer. J Thorac Oncol 2010, 5:620-630.
11. Albain K.S., Crowley J., LeBlanc M., Livingston R.B. Survival determinants in extensive-stage non-small cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol 1991, 1618-1626.
12. Finkelstein D.M., Ettinger D.S., Ruckdeschel J.C. Long-term survivors in metastatic non-small cell lung cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 1986, 4(5):702-709.
13. Hsu C.L., Chen K.y., Shih J.Y., Ho C.C., Yang C.H., Yu C.J., et al. Advanced non-small cell lung cancer in patients aged 45 or younger; outcomes and prognostic factors. BMC Cancer 2012, 12:241-247.
14. Hoang T., Xu R., Schiller J.H., Bonomi Ph., Johnson D.H. Clinical model to predict survival in chemonaive patients with advanced non-small cell lung cancer treated with third generation chemotherapy regimen based on Eastern Cooperative Oncology Group. J Clin Oncol 2005, 23:175-183.
15. Maeda R., Yoshida J., Ishii G., Hishida T., Nishimura M., Kanji Nagai K. Poor prognostic factors in patients with stage IB non-small cell lung cancer according to the seventh edition TNM classification. Chest 2011, 139(4):855-861.
16. Maeda R., Yoshida J., Ishii G., Hishida T., Aokage K., Nishimura M. Long-term survival and risk factors for recurrence in stage I non-small cell lung cancer patients with tumors up to 3cm in maximum diameter. Chest 2011, 138(2):57-62.
17. Berghmans Th., Dusart M., Paesmans M., Hossein-Foucher C., Buvat I., Castaigne C., et al. primary tumor Standardized uptake value measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non small cell lung cancer. J Thorac Oncol 2008, 3:6-12.
18. Cerfolio R.J., Bryant A.S., Ohja B., Bartolucci A.A. The maximum standardized uptake value on positron emission tomography of a non-small cell lung cancer predict stage, recurrence and survival. J Thorac Cardiovasc Surg 2005, 130:151-159.
19. Ignatius Ou S.-H., Zell J.A. Validation study of the proposed IASLC staging revision of the T4 and M non-small cell lung cancer descriptors using data from 23,583 patients in the California cancer registry. J Thorac Oncol 2008, 3:216-227.
20. Ignatius Ou S.-H., Zell J.A. The applicability of the proposed IASLC staging revisions to small cell lung cancer (SCLC) with comparison to the current UICC, 6th edition. J Thorac Oncol 2009, 4:300-310.
21. Morgensztern D., Waqar S., Subramanian J., Trinkaus K., Govindan R. Prognostic impact of malignant pleural effusion at presentation in patients with metastatic non-small cell lung cancer. J Thorac Oncol 2012, 7:1485-1489.
22. Yu J.L., Simmons Ch., Victor J.Ch., Han D., Hogeveen S., Leighi N., et al. Impact of new chemotherapeutic and targeted agents on survival in stage IV non-small cell lung cancer. Oncologist 2013, 2011(16):1307-1315.
23. Sperduto P.W., Berkey B., Gaspar L.E., et al. A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1960 patients in the RTOG database. Int J Radiat Oncol Biol Phys 2008, 70(2):510-514.
24. Morgensztern D., Waqar S., Subramanian J., Gao F., Govindan R. Improving survival for stage IV non-small cell lung cancer. A surveillance, epidemiology, and end results survey from 1990 to 2005. J Thorac Oncol 2009, 4:1524-1529.
25. Owonikoko T.K., Ragin C., Chen Z., Kim S., Behera M., Brandes J.C., et al. Real-world effectiveness of systemic agents approved for advanced non-small cell lung cancer: a SEER Medicare analysis. Oncologist 2013, 18:600-610.
26. Reck M., Heigener D.F., Mok T., Soria J.-Ch., Rabe K.F. Management of non-small-cell lung cancer: recent developments. Lancet 2013, 382:709-719.